Skip to content

Effect of Arabinoxylan and Rye Kernels on Second Meal Responses

Effect of Arabinoxylan and Rye Kernels on Second Meal Responses in Subjects With the Metabolic Syndrome

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01583270
Enrollment
15
Registered
2012-04-24
Start date
2012-04-30
Completion date
2012-10-31
Last updated
2013-06-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Metabolic Syndrome

Keywords

Arabinxylan, Rye kernels, whole grain, Dietary fibre, Metabolic syndrome, Glycemic response, Colon fermentation, Second meal effekt, Satiety

Brief summary

Sedentary lifestyles and increasing obesity are main causes of the global increase in the prevalence of the metabolic syndrome (Mets) and type 2 diabetic (T2DM). Diet quality, particularly composition of carbohydrate play also a significant role. Barley, oat and rye may in addition to reducing the acute post prandial glucose response also reduce glucose response at a subsequent meal. Purified dietary fibre has been shown to reduce GI and affect levels of satiety hormones. In contrast, our knowledge of the physiological effect of arabinoxylan, which constitute a substantial part of dietary fibre in cereal products, is limited in relation to second meal effects. The investigators also lack knowledge of the second meal effect of arabinoxyan in combination with rye kernels. Hypothesis: Porridge rich in arabinoxylan and/or whole rye kernels can increase the formation of short chain fatty acids and improve the glycemic response. The aim of the present study is to compare the effect of porridge test meals based on purified arabinoxylan, rye kernels, a combination of arabinoxylan and rye kernels, and semolina porridge as control on acute postprandial response as well as response at a subsequent standardized meal. The study will be conducted in subjects with the metabolic syndrome. The primary endpoint is glucose response. Secondary endpoints are the following items: insulin, incretins, inflammatory markers, ghrelin, free fatty acids, metabolomics, breath hydrogen and subjective satiety feeling. This project will improve opportunities for identifying and designing foods with low GI that is particularly suited to people who are at high risk of developing T2DM. The investigators also expect to gain a greater understanding of the metabolic fingerprint, as seen after ingestion of low-GI foods and thereby gain a molecular understanding of how low-GI foods affect health by altering metabolic processes. This will give us a deeper insight into the metabolic processes that are necessary for maintaining normal glucose homeostasis

Detailed description

Using a cross-over design, 15 subjects with Mets will consume test meals containing four different porridges in randomized order. Blood samples will be collected over 2 hours after ingestion of test meals and 2 hours after ingestion of a standard second lunch meal served 4 hours after the test meals. The amount of porridge and the standard lunch are equivalent to 50 g available carbohydrate. Visual Analog Scale (VAS) will be used for determination of subjective satiety feeling and measurements of breath hydrogen will be used as a marker for colon fermentation.

Interventions

DIETARY_SUPPLEMENTArabinoxylan

Porridge rich in arabinoxylan

DIETARY_SUPPLEMENTRye kernel

Porridge made of rye kernels

DIETARY_SUPPLEMENTArabinoxylan and rye kernels

Porridgde made of rye kernels and arabinoxylan

DIETARY_SUPPLEMENTSemolina

Semoline porridge. control meal.

Sponsors

University of Aarhus
CollaboratorOTHER
Aarhus University Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
Yes

Inclusion criteria

Central obesity (Female \> 94 cm; Male \> 80 cm) with two of the following: 1. fasting triglyceride (\> 1,7 mmol/L), 2. HDL-cholesterol: (Female:\< 1,03 mmol/L; Male:\< 1,29 mmol/L), 3. blood pressure (≥ 130/85 mmHg) and 4. fasting plasma glucose (≥ 5,6 mmol/L)). Subjects who are in medical treatment with lipid and blood pressure-lowering drugs can continue with their habitual treatment provided that the treatment is stable throughout the trial.

Exclusion criteria

* fasting plasma glucose \> 7,0 mmol/l, * fasting plasma triglyceride \> 5,0 mmol/l, * blood pressure \> 160/100 mmHg , * legal incapacity , endocrine, cardiovascular or kidney disease, * BMI \> 38kg/m2, * corticosteroid treatment, * alcohol or drug addiction and * pregnancy or lactation.

Design outcomes

Primary

MeasureTime frame
Glucose response after second meal2 hours

Secondary

MeasureTime frameDescription
Plasma response after second meal2 hoursPlasma insulin, incretins, ghrelin, short chain fatty acids, freee fatty acids, inflammation markers, and metabolomics.
Plasma response after test meal2 hoursPlasma glucose, insulin, incretins, short chain fatty acids, free fatty acids, metabolomisc.
Breath hydrogen after second meal2 hoursBreath hydrogen as marker for colon fermentation
Breath hydrogen after testmeal2 hoursBreath hydrogen as marker for colen fermentation
Satiety feeling after second meal2 hours
Satiety feeling after test meal2 hours

Countries

Denmark

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026